UiO research prize to Pål Aukrust

Totland MZ, Knudsen LM, Rasmussen NL, Omori Y, Sørensen V, Elster VCW, Stenersen JM, Larsen M, Jensen CL, Zickfeldt Lade AA, Bruusgaard E, Basing S, Kryeziu K, Brech A, Aasen T, Lothe RA, Leithe E (2024)
The E3 ubiquitin ligase ITCH negatively regulates intercellular communication via gap junctions by targeting connexin43 for lysosomal degradation
Cell Mol Life Sci, 81 (1), 171
DOI 10.1007/s00018-024-05165-8, PubMed 38597989

Valsalakumari R, Pandya AD, Prasmickaite L, Kvalvaag A, Myrann AG, Åslund AKO, Kjos MS, Fontecha-Cuenca C, Haroon HB, Ribeiro ARS, Horejs-Hoeck J, Moghimi SM, Mørch Ý, Skotland T, Sandvig K, Mælandsmo GM, Iversen TG (2024)
Preclinical Efficacy of Cabazitaxel Loaded Poly(2-alkyl cyanoacrylate) Nanoparticle Variants
Int J Nanomedicine, 19, 3009-3029
DOI 10.2147/IJN.S450283, PubMed 38562610

Skipar K, Hompland T, Lund KV, Lindemann K, Hellebust TP, Bruheim K, Lyng H (2024)
MRI-guided dynamic risk assessment in cervical cancer based on tumor hypoxia at diagnosis and volume response at brachytherapy
Radiother Oncol, 195, 110263 (in press)
DOI 10.1016/j.radonc.2024.110263, PubMed 38556173

Meriranta L, Sorri S, Huse K, Liu X, Spasevska I, Zafar S, Chowdhury I, Dufva O, Sahlberg E, Tandaric L, Karjalainen-Lindsberg ML, Hyytiainen M, Varjosalo M, Myklebust JH, Leppa S (2024)
Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-cell Lymphoma
Blood Cancer Discov (in press)
DOI 10.1158/2643-3230.BCD-23-0182, PubMed 38630892

Grindedal EM, Zucknick M, Stormorken A, Rønne E, Tandstad NM, Isaacs WB, Axcrona K, Mæhle L (2024)
Outcomes of 10 years of PSA screening for prostate cancer in Norwegian men with Lynch syndrome
Prostate (in press)
DOI 10.1002/pros.24711, PubMed 38629217

Suske T, Sorger H, Manhart G, Ruge F, Prutsch N, Zimmerman MW, Eder T, Abdallah DI, Maurer B, Wagner C, Schönefeldt S, Spirk K, Pichler A, Pemovska T, Schweicker C, Pölöske D, Hubanic E, Jungherz D, Müller TA, Aung MMK, Orlova A, Pham HTT, Zimmel K, Krausgruber T, Bock C et al. (2024)
Hyperactive STAT5 hijacks T cell receptor signaling and drives immature T cell acute lymphoblastic leukemia
J Clin Invest, 134 (8)
DOI 10.1172/JCI168536, PubMed 38618957